Navigation Links
Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
Date:10/29/2007

ese statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate; our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facility; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; an increase in litigation, including product liability claims and patent litigation; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our a
'/>"/>

SOURCE Warner Chilcott Company, Inc.; Watson Pharmaceuticals,Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Charter and Time Warner to partner on fiber optics
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. The Coming of Biotech Generic Pharmaceuticals
4. Speaker announces business members of IT Task Force
5. Doyle announces technology tax credits for Berbee
6. Doyle announces new energy, global warming policies
7. Doyle, WARF announce partnership to lure stem cell companies
8. Doyle announces $80M renewable energy strategy
9. GE announces first installation of Discovery VCT
10. UWM announces winners of RGI awards
11. Third Wave announces two senior management appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... -- Adaptive Biotechnologies announced today that Chad Cohen ... Director as Chair of the Audit Committee. ... all finance, treasury and accounting functions. Since joining Zillow ... and accounting functions, and led the finance organization through ... was named Puget Sound Business Journal,s CFO of the ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Crown Bioscience, ... company, has launched a new Life Science division specializing ... preclinical research. , The first products released include ... controls, and soon to be released in vivo grade ... continue to expand their life science portfolio with additional ...
(Date:3/3/2015)... , March 3, 2015 Fried, Frank, ... Jeffrey I.D. Lewis has joined the Firm as ... in the New York office. ... trademark matters, as well as other intellectual property and ... attorney, Mr. Lewis represents both plaintiffs and defendants in ...
(Date:3/3/2015)... March 03, 2015 HubCast® Inc. ( ... today announced the expansion of its Global Print Supply ... to 850 the world’s largest cities across 75 countries ... to 137 countries providing global enterprises ease, speed, reach, ... process from online order to real-world delivery at postal ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Crown Bioscience Launches Life Science Product Catalog 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4
... (Nasdaq: IDIX ) announced today that it will ... on Thursday, October,30, 2008 after the U.S. financial markets ... press release, Idenix,management will host a conference call at ... the company,s financial results for the third quarter,of 2008 ...
... 20 The Cure Our Children Foundation,a nonprofit ... U.S. Food and Drug Administration (FDA) has approved ... product for children with,Ewing,s Sarcoma cancer. The efforts ... generous volunteers and researchers in private industry and ...
... implementation of a,compliant Laboratory Information Management System (LIMS) ... "scope creep," with costs,rising 2 to 5 times ... a seemingly never-ending project. But a new white ... to cut the technical,resources and costs required for ...
Cached Biology Technology:FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children 2White Paper Examines New 'Thin LIMS' IT Implementation Strategy for cGMP Quality Informatics 2
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
(Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... for helping men get big results, but for those who need ... report published online in The FASEB Journal , ... often seen in men with sickle cell disease, causes erections lasting ... a compound, called "C6," offered mice -- with and without sickle ...
... membrane of bacteria contains many proteins that form tiny ... signals into the cell. The research group of Sebastian ... of Basel, has now shown for the first time ... in an unstructured, constantly changing state to the outer ...
... new treatment for glioblastoma suggest that researchers may have ... of brain tumours, as well as a potential new ... treatment. Presenting the research to the 2013 European ... will say that combining radiotherapy with an anti-cancer drug ...
Cached Biology News:Beyond the little blue pill: scientists develop compound that may treat priapism 2Erratic proteins: New insights into a transport mechanism 2Erratic proteins: New insights into a transport mechanism 3Trial combining anti-cancer drug and radiotherapy may lead to treatment for brain tumor 2Trial combining anti-cancer drug and radiotherapy may lead to treatment for brain tumor 3
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
... recombinant human angiogenin expressed in ... Physical form: Lyophilized from a ... phosphate buffered saline. Titertest ... Titertest values: capture ELISA ...
Request Info...
Biology Products: